Kornimate/medical-research-clean huggingface dataset:
chloroquine diphosphate in the prevention of sars in covid-19 infection

Conditions: COVID-19; SARS-CoV Infection; Severe Acute Respiratory Syndrome (SARS) Pneumonia; Clinical Trial

Summary: this is a double-blind, randomized, placebo-controlled clinical trial. a total of 210 individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who came to the study site with clinical and radiological suspicion of sars-cov2, will be randomized into two treatment groups at a 1:1 ratio to receive a 5-day cq diphosphate tablets or placebo (tablet without active ingredient produced with the same physical characteristics).


Eligibility criteria:
inclusion criteria: 1. suspected cases of covid-19, due to clinical and radiological data, during the epidemic; 2. adult aged 18 or over, at the time of inclusion 3. not having severe acute respiratory syndrome (sars), that is, not using mechanical ventilation or supplemental oxygen, peripheral oxygen saturation\> 94% in room air, and having a respiratory rate below 24 incursions per minute. 4. patients with comorbidities only, due to the increased risk of developing sars exclusion criteria: 1. patients with chronic use of drugs known to prolong qtc interval.
safety and efficacy of acei in alport syndrome patients with col4a3/col4a4/col4a5 variants

Conditions: Alport Syndrome

Summary: alport syndrome (as) is the second most common monogenic cause of end-stage renal failure (esrf). as is caused by variants in the col4a3, col4a4, and col4a5 genes, which encode for the a3, a4, and a5 chains of type iv collagen. this trial is a prospective, randomized, controlled and multicenter trial. mainly to assess the safety and efficacy of ramipril in alport syndrome patients with variants of col4a3/col4a4/col4a5.


Eligibility criteria:
inclusion criteria: 1. age: 30-50 years; 2. sex: all; 3. alport syndrome patients with variants of col4a3/col4a4/col4a5; hematuria or microalbuminuria; egfr\>90 ml/min/1.73m2; 4. patients with microscopic hematuria only; 5. patients with microscopic hematuria and microalbuminuria: 30-300mg/24h or urine albumin/creatinine: 30-300mg/g; 6. no angiotensin converting enzyme inhibitor (acei) and other renin-angiotensin system inhibitors (including angiotensin ii receptor antagonists, etc.) treatment. exclusion criteria: 1. with primary or secondary kidney disease, including iga nephropathy, membranous nephropathy, lupus nephropathy, benign renal arterioles, etc.; 2. patients with a history of angioedema; 3. hypovolemia or hypotension (systolic blood pressure less than 90mmhg and/or diastolic blood pressure less than 60mmhg); 4. pregnant and lactating women; 5. patients with bilateral renal artery stenosis or unilateral renal artery stenosis with solitary kidney; 6. hyperkalemia, blood potassium\>5.5mmol/l; 7. severe aortic stenosis, severe mitral stenosis; 8. treatment of drug allergy; 9. hypertension or other diseases that may require treatment with angiotensin-converting enzyme inhibitors; 10. disagree to participate in this research.
randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to evaluate whether the newly-approved everolimus-eluting stent is not inferior to the sirolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year after stent implantation in the real world clinical practice.

sirolimus-eluting stent is the most widely used coronary drug-eluting stent in japan. everolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in the first quarter of 2010 by the japanese ministry of health, labor and welfare. it has recently been reported that everolimus-eluting stent had lower rate of target-lesion revascularization and stent thrombosis at 1 year as compared with paclitaxel-eluting stent. however, trial results comparing everolimus-eluting stent with sirolimus-eluting stent are largely unknown. the purpose of this study is to evaluate whether the newly-approved everolimus-eluting stent is not inferior to the sirolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year after stent implantation in the real world clinical practice. the design of this study is all-comer design enrolling patients scheduled for percutaneous coronary intervention using drug-eluting stents without any exclusion criteria.

Eligibility criteria:
inclusion criteria: * patients scheduled for percutaneous coronary intervention using drug-eluting stents exclusion criteria: * none

Keywords: coronary stent
medication adherence in rheumatic diseases

Conditions: Chronic Rheumatic Diseases

Summary: the investigators will pilot test a clinician-led intervention to improve medication adherence in general rheumatology clinic across a spectrum of rheumatic diseases. the study will assess feasibility, acceptability, and fidelity, and explore signal for improved medication adherence.


Eligibility criteria:
inclusion criteria: * all providers at southpoint rheumatology all patients with a rheumatic disease diagnosis currently prescribed at least one rheumatic medication will be included in the analysis exclusion criteria: * new patients, those who are not prescribed any rheumatic disease medications, or do not have available pharmacy refill data
long-term sequelae of childhood meningitis and meningococcal purpura fulminans

Conditions: Meningitis, Meningococcal; Sequela

Summary: while the initial evolution of meningococcal meningitis (mm) is well described, there are few data on the long-term evolution, beyond 1 year. the objective of this research is to evaluate the sequelae of mm beyond 1 year in patients with a history of mm followed in paris area, france. most children with mm in france have been included in the mm register and are still being followed. parents will be offered a detailed clinical evaluation of their child including: a clinical and neurological examination, a cognitive performance assessment, an auditory, speech and visual assessment and an evaluation of the child's progress at school.


Eligibility criteria:
inclusion criteria: * infants and children from 0 to 17 years old * having had meningitis or meningococcal purpura fulminans between 2010 and 2021 * delay ≥ 1 year between the date of diagnosis of meningitis or purpura meningococcal fulminans and the date of inclusion in the study (signature of the informed consent) * the holders of parental authority have read and understood the information letter and their express consent has been obtained * patient affiliated to a social security system (social security or universal medical coverage) exclusion criteria: * refusal to participate
study of immune cells in obese patients with type 2 diabetes mellitus treated with liraglutide

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes. the hypotheses are: * glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood * treatment with glucagon-like peptide-1 increases the number of immune cells in the blood * treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood


Eligibility criteria:
inclusion criteria: * type 2 diabetes * bmi \> 27 kg/m2 * planed start of treatment with liraglutide * age \> 18 years exclusion criteria: * infection or active inflammatory disorder * immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids) * smoking * alcohol consumption \> 14 beverages/week * former bariatric surgery
gynaecological follow-up of a subset of 580299/008 (nct00122681) study subjects

Conditions: Infections, Papillomavirus

Summary: this study is designed to provide up to four years of annual oncogenic hpv dna testing and cervical cytology examination for nct00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic hpv infection at their last nct00122681 study visit (visit 10, month 48). this follow-up study will also be offered to subjects who were pregnant at their last nct00122681 study visit (visit 10, month 48) so that no cervical sample could be collected at that visit. the objectives \& outcome measures of the primary phase (study 008/580299) are presented in a separate protocol posting (nct00122681).


Eligibility criteria:
inclusion criteria: * written informed consent obtained from the subject prior to enrolment. * subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * a subject previously enrolled in the study nct00122681 and who fulfils either of the following criteria: * displayed normal cervical cytology but tested positive for oncogenic hpv infection at her last nct00122681 study visit (visit 10, month 48). or - was pregnant at her last visit of the nct00122681 study (visit 10, month 48) so that no cervical sample could be collected at that visit. exclusion criteria: * a subject who displayed normal cervical cytology and who was negative for oncogenic hpv infection at her last nct00122681 study visit (visit 10, month 48). * a subject who had a cervical lesion at her last nct00122681 study visit (visit 10, month 48) or who had a cervical lesion that required treatment at the nct00122681 exit colposcopy. * a subject for whom the cervical cytology results from the last nct00122681 study visit (visit 10, month 48) were unavailable for reasons other than pregnancy. if at the time of enrolment the subject experiences heavy bleeding (menstruation or other) or heavy vaginal discharge, or is pregnant, the pelvic exam cannot be performed. the subject's first study visit will be deferred until condition is resolved according to investigator's medical judgment.

Keywords: hpv papillomavirus human papillomavirus cervical cancer hpv vaccine
safety and efficacy study of tendril mri™ leads in standard bradycardia pacing indication

Conditions: Bradycardia

Summary: the purpose of this observational study is the assessment (safety and efficacy) of the st. jude medical tendril mri™ leads. the tendril mri™ leads are a full part of the accent mri™ system, consisting of tendril mri™ leads and accent mri™ pacemaker. the subject population includes patients with a standard bradycardia pacing indication.

magnetic resonance imaging (mri) is a diagnostic method to view high quality two and three dimensional images of the body. however, magnetic resonance imaging systems generate three electromagnetic fields that are used to produce an image. these include a static magnetic field, a time varying gradient magnetic field, and a radiofrequency field. all three of these fields interact with implanted devices and could create hazards for the device, the patient, or both. due to these issues, currently marketed pacemaker systems may be contraindicated for use in an mri environment. st. jude medical has developed a system, the accent mri™ system, comprised of the accent mri™ device and the tendril mri™ lead, and an investigational mri activator™, designed to mitigate such interactions.

Eligibility criteria:
inclusion criteria: * approved class i or class ii indication per: european society of cardiology (esc) guidelines for implantation of a dual chamber pacemaker or single chamber pacemaker, or american college of cardiology (acc) / american heart association (aha) / heart rhythm society (hrs) guidelines for implantation of a dual chamber pacemaker or single chamber pacemaker * require a new accent mri™ pacemaker and tendril mri™ lead (either initial implant or complete system change out with no abandoned devices). * is ≥ 18 years of age. * able to provide written informed consent prior to any investigational related procedure. * willing and able to comply with the prescribed follow-up tests and schedule of evaluations. exclusion criteria: * have an existing pacemaker or icd (abandoned devices and/or leads are not allowed. a new pacemaker and lead or complete system change out is required for enrollment). * have an existing active implanted medical device (e.g., implantable cardioverter defibrillator (icd), neurostimulator, etc.). * have a non-mri compatible device or material implant (e.g., intracranial aneurysm clip, non-mri compatible devices or material, metals or alloys, etc.). * have a lead extender, plug or adaptor. * have a prosthetic tricuspid heart valve. * are currently participating in another investigational device or drug investigation. * are allergic to dexamethasone sodium phosphate (dsp). * are pregnant or planning to become pregnant during the duration of the study. * have a life expectancy of less than 12 months from screening due to any life-threatening condition
telerehabilitation in patients with osteoarthritis

Conditions: Osteoarthritis

Summary: randomized controlled study on the effectiveness of telerehabilitation intervention on subjects with knee osteoarthritis. subjects will be randomized into two groups. the experimental group perform 3 sessions a week for 4 weeks of tr, the control group 3 sessions a week for 4 weeks of conventional rehabilitation c/o ior rehabilitation gym. follow-up at 3 months. inclusion criteria 1. subjects must have a diagnosis of rheumatologic disease, osteoarthritis of one or more indications, oarsi criteria. 2. male or female, aged \&gt; 18 years 3. participant is willing and able to provide informed consent for participation in the study. 4. subjects must be able to use an electronic device (pc, tablet, smartphone). exclusion criteria 1. participation in another clinical study with any investigational agent within 30 days prior of the study screening. 2. inability to use an electronic device (pc, tablet, smartphone) 4. diagnosed with dementia or neurological disease that impairs speech comprehension e not verbal. 5. uncontrolled intercurrent illnesses including, without limitation, current infection or active, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illnesses/social situations that would limit compliance with study requirements, illnesses neurological. 6. children under the age of 18 8. nprs value \ 25


Eligibility criteria:
inclusion criteria: * subjects must have a diagnosis of rheumatologic disease, osteoarthritis of one or more articulations, oarsi criteria. * male or female, aged \&gt; 18 years * participant is willing and able to provide informed consent for participation in the * study. * subjects must be able to use exclusion criteria: * participation in another clinical study with any investigational agent within 30 days prior * of the study screening. * inability to use an electronic device (pc, tablet, smartphone) * diagnosed with dementia or neurological disease that impairs speech comprehension e not verbal. * uncontrolled intercurrent illnesses including, without limitation, current infection or active, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illnesses/social situations that would limit compliance with study requirements, illnesses neurological. * hildren under the age of 18 * numeric pain rating scale(nprs) value \<3 * bmi \>25
a study of single-agent eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor two (her2) negative breast cancer

Conditions: Locally Recurrent; Metastatic Breast Cancer ( HER2 Negative)

Summary: the purpose of this study is to assess the efficacy and safety of single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or metastatic breast cancer.

this is a multicenter, single-arm, phase 2 trial to assess the efficacy and safety of single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or metastatic human epidermal growth factor receptor (her2)-negative breast cancer. a total of 52 adult female subjects will be enrolled and treated with eribulin mesylate (1.4 mg/m2 as an intravenous \[i.v.\] infusion over 2 to 5 minutes on days 1 and 8 of each 3-week cycle).

Eligibility criteria:
key inclusion criteria females age 18 years or older at the time of informed consent have histologically or cytologically proven adenocarcinoma of the breast subjects with locally recurrent or metastatic disease with at least one measurable lesion according to response evaluation criteria in solid tumors (recist) criteria v 1.1 human epidermal growth factor receptor (her2)-negative disease as determined by fluorescence in situ hybridization (fish) or 0 or 1+ by immunohistochemical (ihc) staining. life expectancy of greater than 24 weeks eastern cooperative oncology group (ecog) performance score (ps) of 0, 1 or 2 at least 12 months since prior neoadjuvant or adjuvant chemotherapy at least 2 weeks since prior radiotherapy or endocrine therapy, with complete recovery from the effects of these interventions adequate renal function adequate bone marrow function adequate liver function key exclusion criteria subjects who meet any of the following criteria will be excluded from participation in this study: prior chemotherapy, biologic therapy, or investigational therapy for locally recurrent or metastatic breast cancer subjects who have had a prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer prior exposure of greater than 360 mg/m2 doxorubicin or liposomal doxorubicin, greater than 120 mg/m2 mitoxantrone, greater than 90 mg/m2 idarubicin, or greater than720 mg/m2 epirubicin inflammatory breast cancer clinically significant cardiovascular impairment subjects with known cns disease are not eligible, except for those with treated brain metastasis. pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring the use of oxygen currently pregnant or breast-feeding. subjects with pre-existing grade 3 or 4 neuropathy. any peripheral neuropathy must recover to grade 2 before enrollment.
hr070803 in combination with oxaliplatin, 5-fu/lv versus ag for first-line treatment of advanced pancreatic cancer

Conditions: First-line Treatment of Advanced Pancreatic Cancer

Summary: the purpose of this study is to look at the efficacy and safety of hr070803 in combination with 5 fluorouracil/leucovorin (5fu/lv) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. ecog performance status 0 or 1 2. histological or cytologically confirmed pancreatic cancer that has not been previously treated in the metastatic disease. 3. life expectancy of greater than or equal to3 months. 4. at least one measurable lesion is present according to the efficacy evaluation criteria for pancreatic cancer (recist 1.1) 5. able and willing to provide a written informed consent exclusion criteria: 1. patients with pancreatic cancer originating from extrapancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas, pancreatoblastoma, and solid-pseudopapillary tumor; 2. known history of central nervous system (cns) metastases. 3. severe infection (\> ctcae grade 2), such as severe pneumonia, bacteremia, infection complications, etc. requiring inpatient treatment, occurred within four weeks before enrollment, and symptoms and signs of infection requiring intravenous antibiotic therapy (except for prophylactic antibiotics) occurred within two weeks before enrollment; 4. patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) patients with nyha class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within 6 months; (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
reliability of the smartphone inclinometer app and flexicurve

Conditions: Disorder; Kyphosis Deformity of Thoracic Spine

Summary: the presedent study evaluates intra-rater and inter-rater reliability of the smartphone inclinometer app and the flexicurve, on the thoracic kyphosis

sixty subjects ranging from 17to 24 years of age were evaluated by two independent evaluators using the flexicurve and the smartphone inclinometer app to measure thoracic kyphosis

Eligibility criteria:
inclusion criteria: * over 30 degree toracic kyphosis, * 18-30 age year old, * individuals to willing participate in the study exclusion criteria: * skolyoz (cobb angle 10\< ), * rigid thoracic kyphosis, * congenital spine disease, * training with professional sports
swiss hemophilia registry

Conditions: Hemophilia and Other Severe Bleeding Disorders

Summary: the swiss hemophilia registry will collect data on the prophylactic and therapeutic use of factor concentrates in patients with hemophilia and other severe bleeding disorders in switzerland.


Eligibility criteria:
inclusion criteria: diagnosis of hemophilia or other severe bleeding disorders. signed inform consent exclusion criteria: none
radiosurgery and avastin for recurrent malignant gliomas

Conditions: Malignant Glioma

Summary: the purpose of this study is to assess the central nervous system (cns) toxicity in patients with recurrent malignant gliomas treated with concurrent avastin and stereotactic radiosurgery (srs).

in this pilot study, 15 human subjects with recurrent, unifocal malignant gliomas up to 5-cm in maximum dimension no longer responding to conventional chemotherapy but able to tolerate further chemotherapy will be enrolled. the primary endpoint of this study will be the proportion of patients who experience cns toxicity, with secondary endpoints progression-free survival, overall survival, steroid dosage, development of radionecrosis, quality of life, objective radiographic response and performance status.

Eligibility criteria:
inclusion criteria: * history of malignant glioma (who grade iii or iv) of the brain treated with some combination of surgery, biochemotherapy and conventionally fractionated external beam radiotherapy * radiotherapy completed at least 6 months prior to recurrence * age 18 years and older * new or enlarging contrast-enhancing and/or 18fdg-avid nodule, at least 1 cm diameter * estimated life expectancy of 3 months or longer exclusion criteria: * avastin therapy within 21 days of start of participation * contraindication to avastin therapy or brain mri * presence of bleeding diathesis or coagulopathy * history of prior arterial thrombotic event, myocardial infarction, angina, cva, tia, cabg angioplasty or stenting within 6 months. * inadequately controlled hypertension (defined as systolic blood pressure * new york heart association (nyha) grade ii or greater congestive heart failure * clinically significant vascular disease * major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to onset of treatment * prior history of hypertensive crisis or hypertensive encephalopathy * history of abdominal fistula or gi perforation within 6 months prior to onset of treatment * serious non-healing wound, active ulcer or untreated bone fracture * proteinuria demonstrated by urine protein creatinine ratio \> 1.0 * pregnancy

Keywords: recurrent